Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - ATHERSYS, INC / NEW | c13875e10vk.htm |
| EX-21 - EXHIBIT 21 - ATHERSYS, INC / NEW | c13875exv21.htm |
| EX-23 - EXHIBIT 23 - ATHERSYS, INC / NEW | c13875exv23.htm |
| EX-31.2 - EXHIBIT 31.2 - ATHERSYS, INC / NEW | c13875exv31w2.htm |
| EX-32.1 - EXHIBIT 32.1 - ATHERSYS, INC / NEW | c13875exv32w1.htm |
| EX-31.1 - EXHIBIT 31.1 - ATHERSYS, INC / NEW | c13875exv31w1.htm |
| EX-24.1 - EXHIBIT 24.1 - ATHERSYS, INC / NEW | c13875exv24w1.htm |
| EX-10.48 - EXHIBIT 10.48 - ATHERSYS, INC / NEW | c13875exv10w48.htm |
| EX-10.47 - EXHIBIT 10.47 - ATHERSYS, INC / NEW | c13875exv10w47.htm |
EXHIBIT 10.41
SUMMARY OF ATHERSYS, INC.
2011 CASH BONUS INCENTIVE PLAN
2011 CASH BONUS INCENTIVE PLAN
On March 25, 2011, the Board of
Directors of Athersys, Inc. (the “Company”), upon the
recommendation of the Compensation Committee of the Board of Directors of the Company, approved a
cash bonus incentive plan (the “Plan”) for the year ended December 31, 2011 for the named
executive
officers of the Company. The Plan provides that each participant is eligible to earn a bonus during
the award term of January 1, 2011 through December 31, 2011. The Plan provides for the following
target bonus percentages of the named executive officer’s salary during the award term, weighted as
set forth below on the achievement of specified corporate goals, with the remainder based on
individual/functional performance. The corporate goals include advancing the Company’s clinical
programs for MultiStem, executing against the established operating plan and capital acquisition
objectives, and advancement of strategic partnership and program activities. There is no formally
adopted plan document for the Plan.
| Target | Weighting on | |||||||
| Title | Bonus | Corporate Goals | ||||||
Chief Executive Officer |
40 | % | 100 | % | ||||
President & Chief Operating Officer |
33 | % | 80 | % | ||||
Executive Vice President &
Chief Scientific Officer |
33 | % | 80 | % | ||||
Sr. Vice President,
Regenerative Medicine |
30 | % | 60 | % | ||||
Vice President of Finance |
25 | % | 60 | % | ||||